Page 6,611«..1020..6,6106,6116,6126,613..6,6206,630..»

Genetic disorder means daily battle with calculated risks

Posted: Published on August 1st, 2012

By MEGAN GRAHAM In his old room in his parents' home, a pretty house in the Cherry Hills subdivision of Champaign, Chike Coleman is poking through his shelves. He wants to find a Blu-ray disc, one of the beloved movies he bought in a half-off online sale from a site that sells independent films. He moves aside tens of his prized jazz CDs, the Soapbox Derby trophies and the Hardy Boys books. The shelves are filled with 25 years of memories: books he has loved, model cars done in candy-colored lacquer, his University of Illinois diploma. His high school and college friends most 25-year-olds, for that matter no longer live in the dust of their boyhood belongings. But after his fleeting years of collegiate freedom, Chike moved right back into this room, with its boxes of waterproof dressing and nonstick pads and bandages, bottles of hydrogen peroxide, soap-free cleanser and Clindamycin gel. "It's just kind of waiting," he says. "Just like everybody else. Except your wait feels a lot shorter than everybody else's." Chike glances at a photograph of him leaning back casually in his wheelchair, royal blue graduation gown draping his chest as he smiles broadly. He looks normal. … Continue reading

Comments Off on Genetic disorder means daily battle with calculated risks

Ashkenazi Jewish Genetic Disease Carrier Screening Now More Affordable in the New York Metropolitan Area

Posted: Published on August 1st, 2012

The Program for Jewish Genetic Health of Yeshiva University / Einstein is offering accessible and affordable carrier screening for Jewish genetic diseases. New York, New York (PRWEB) August 01, 2012 The Program for Jewish Genetic Health (PJGH) of Yeshiva University/Einstein has announced that it has enabled the most affordable and comprehensive Ashkenazi Jewish genetic disease carrier screening to date in the New York metropolitan area. Carrier screening via the PJGH, which includes individual genetic counseling sessions for each participant, is offered through the clinical services of the Division of Reproductive Genetics of Montefiore Medical Center/Einstein. The PJGH advocates that individuals and couples undergo genetic screening prior to conception; many health insurance policies, however, will provide only partial coverage at that stage. To address this issue, the PJGH, with assistance from its philanthropic and laboratory partners, has been facilitating low-cost screening for both uninsured and underinsured patients for several years. Thanks to a new relationship with leading genetic testing company Counsyl, who only recently received accreditation from the New York State Department of Health for the testing of New York State residents, the PJGH is able to further lower the cost of screening for all individuals. We are thrilled to be … Continue reading

Comments Off on Ashkenazi Jewish Genetic Disease Carrier Screening Now More Affordable in the New York Metropolitan Area

23andMe Genetic Testing Company Applies For FDA Approval

Posted: Published on August 1st, 2012

August 1, 2012 Connie K. Ho for redOrbit.com Your Universe Online 23andMe, a company focused on personal genetics, recently took the first step in working towards Food and Drug Administration (FDA) clearance; the FDA plans to review the paperwork over the next few months. Previously, the Silicon Valley company refrained from government regulation, claiming that the service provided consumers with information rather than a medical service. CBS News reported that 23andMe submitted the first group of seven health-related tests for the FDA to review. By the end of next year, the organization will have submitted another 100 tests to the agency. With these exams, the organization hopes to obtain government approval and scientific credibility. 23andMe has pioneered the direct-to-consumer genetic testing industry and we are committed to helping individuals understand their own genetic information through proven DNA analysis technologies and web-based interactive tools, commented Anne Wojcicki, 23andMe CEO and Co-Founder, in a prepared statement. 23andMe is working proactively with the FDA to ensure the industry delivers high quality information that consumers can trust. 23andMes Personal Genome Service allows individuals to learn more about their personal DNA, offering over 200 health and trait reports along with information on genetic ancestry. The … Continue reading

Comments Off on 23andMe Genetic Testing Company Applies For FDA Approval

Stem Cell Therapy Only Works With Younger Hearts

Posted: Published on August 1st, 2012

Editor's Choice Main Category: Stem Cell Research Also Included In: Biology / Biochemistry Article Date: 31 Jul 2012 - 14:00 PDT Current ratings for: Stem Cell Therapy Only Works With Younger Hearts The researchers, using mice as their subjects, came to the conclusion that undifferentiated precursor cells grow new heart cells in a two-day-old mouse, but not in adult mice. This finding settled a decades-old debate whether or not stem cells can play a role in the recovery of the adult mammalian heart after infarction (when heart tissue dies due to a local lack of oxygen). Stem cells are biological cells found in all multicellular organisms. They are characterized by the ability to divide through mitosis and differentiate into diverse specialized cell types. They can self-renew to produce more stem cells. Michael Kotlikoff, dean of Cornell's College of Veterinary Medicine and senior author of the paper that will appear August 29th in the Proceedings of the National Academy of Sciences, said: According to Kotlikoff and team, the two-day old mice were able to grow new heart cells and almost completely recover from infarction, which proved that the injury did not stop stem cells from growing new heart cells. The results … Continue reading

Comments Off on Stem Cell Therapy Only Works With Younger Hearts

Cell Therapeutics, Inc. (CTI) Readies Pixuvri® European Launch and Start of Pacritinib Phase 3 Trial; Reports Second …

Posted: Published on August 1st, 2012

SEATTLE, Aug. 1, 2012 /PRNewswire/ --Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported financial results and recent accomplishments for the second quarter of 2012. Recent Company Highlights "Based on in-market research among more than 250 lymphoma specialists in the five major market countries in the European Union ("EU"), we are encouraged by the interest and potential adoption of Pixuvri for treatment," stated James A. Bianco, M.D., President and CEO of CTI. "We believe we can present an argument for Pixuvri to provide fair pricing reimbursement in an effort to address the commercial potential of Pixuvri in the E.U. On the heels of our projected fourth quarter launch of Pixuvri in the E.U., we expect to start pivotal studies of our recent JAK2 product acquisition, pacritinib. In the meantime, we are also advancing tosedostat toward its phase 3 clinical trial." Financial Results For the quarter endedJune 30, 2012, total operating expenses were$49.4 millioncompared to$16.9 millionfor the same period in 2011. The increase is predominantly due to an acquired in-process research and development expense of $29.1 million relating primarily to the acquisition of pacritinib from S*BIO Pte Ltd. ("S*BIO"), in addition to equity-based compensation and expenses related … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Cell Therapeutics, Inc. (CTI) Readies Pixuvri® European Launch and Start of Pacritinib Phase 3 Trial; Reports Second …

Lame dogs brought to heal with stem cells Save

Posted: Published on August 1st, 2012

July 29, 2012, 3 a.m. Up for a walk ... Denise Stuckey, with her dog, Bella, who has had stem cell treatment from vet Joe Sulyok. Stem cell injections in dogs will become routine in the next two years and will probably cost less than $1000. The first data, collated last week, into the use of the procedure where cultured cells are injected into the joints of dogs with hip dysplasia or canine osteoarthritis has shown a success rate of 96 per cent. The procedure will be made available to veterinary clinics, promoted at dog shows and possibly in a television campaign. It has been transformed in little more than a year with stem cells from one animal used to treat other dogs. Previously, an invasive procedure was necessary, with incisions to remove subcutaneous or fatty tissue from the affected dog and stem cells isolated in a laboratory before being injected back into the dog. The procedure resulted in a culture containing only about 10 per cent to 15 per cent stem cells, while the culture from a donor in a breed with a genetic line clear of arthritis can been screened to provide a culture containing 100 per cent … Continue reading

Comments Off on Lame dogs brought to heal with stem cells Save

Removing kidney increases risk of erectile dysfunction

Posted: Published on July 31st, 2012

Removal of a kidney can greatly increase the risk of erectile dysfunction. (National Library of Medicine / National Institutes of Health) July 31, 2012, 11:43 a.m. Total removal of a kidney during cancer treatment increases the risk of developing erectile dysfunction nearly four-fold compared with patients who have only a partial removal, researchers reported Tuesday. In light of other research, which shows that partial removal (known as partial nephrectomy) is at least as effective and probably more effective than complete removal (radical nephrectomy), it now seems reasonable that radical nephrectomy should be reserved as a last resort. Dr. Ithaar Derweesh, a urologic surgeon at the UC San Diego Health System, and his colleagues studied 264 patients who underwent a radical nephrectomy and 168 who underwent a partial nephrectomy at either the UC San Diego Medical Center or the University of Tennessee Health Science Center in Memphis between January 1988 and December 2007. The team assessed the patients' sexual health and activity before the surgery and at least six months afterward. The researchers reported in the British Journal of Urology International that the patients who had radical nephrectomies had larger tumors and were more likely to have erectile dysfunction before cancer … Continue reading

Posted in Erectile Dysfunction | Comments Off on Removing kidney increases risk of erectile dysfunction

FDA Approves Qsymia Diet Drug, with Warnings About Side Effects

Posted: Published on July 31st, 2012

Posted by Eric ChaffinJuly 31, 2012 9:45 AM Most of us know that our country is in the grips of an obesity epidemic. Doctor recommended diet and exercise programs have not controlled the problem, so pharmaceutical companies are hard at work coming up with other solutions. Last month, the FDA approved Belviq (lorcaserin) as a weight-loss drug for those with a body mass index (BMI) of 30 or greater. More recently, the FDA approved Qsymia (phentermine and topiramate extended-release) for chronic weight management in addition to a reduced-calorie diet and exercise. These drugs come with potentially serious side effects, and it seems like once again the public is taking part in a giant experiment. For example, federal officials are requiring post-marketing studies to look for evidence of increased heart disease or stroke risk in those who take Qsymia. Concerns About Cardiovascular Risks It was only about a year-and-a-half ago that the FDA rejected manufacturer Vivus first petition to approve Qsymia (pronounced kyoo sim EE uh). Among other things, the agency was concerned that the drug could increase the risk of heart attack and stroke. The FDA rejected Belviq in an earlier request for approval because of similar concerns. Experts believe … Continue reading

Posted in Drug Side Effects | Comments Off on FDA Approves Qsymia Diet Drug, with Warnings About Side Effects

AmerisourceBergen wins crucial contract with Express Scripts

Posted: Published on July 31st, 2012

In crucial deal for AmerisourceBergen, Inc., the Valley Forge-based drug wholesaler said it won a three-year contract worth approximately $18.5 billion per year in revenue in exchange for supplying pharmaceutical products to Express Scripts. We are honored that Express Scripts has chosen AmerisourceBergen to supply the brand pharmaceuticals it needs for its recently combined mail order and specialty pharmacy business, Steven H. Collis, AmerisourceBergen president and chief executive officer, said in a statement. This was important for Collis and AmerisourceBergen's 13,000 employees - including 1,100 in three local facilities - because the revenue essentially replaces that which came from Medco Health Solutions. Losing 19 percent of revenue would hurt any company and perhaps prompt layoffs. Medco was bought out by Express Scripts, making it the largest mail-order drug company and the largest pharmacy benefits manager, sometimes referred to in the industry at PBMs. PBMs are paid by companies to manage the drug portion of employer-sponsored health insurance programs. With the acquisition of Medco completed, St. Louis-based Express Scripts requested proposals from the three largest wholesale drug companies: McKesson, Cardinal Health and AmerisourceBergen. Though 29th on the Fortune 500 list with $80 billion in revenue, AmerisourceBergen is the smallest of the … Continue reading

Posted in Wholesale Pharmacy | Comments Off on AmerisourceBergen wins crucial contract with Express Scripts

Cost of supporting South Cumbria addicts is revealed

Posted: Published on July 31st, 2012

Last updated at 16:22, Tuesday, 31 July 2012 THE cost to the taxpayer for supporting drug addicts and alcoholics across Barrow, South Lakeland and Copeland through benefits is a staggering 32,000 a week. Figures released by the government show the total includes people on Incapacity Benefit and Employment and Support Allowance where they cite the primary reason for claiming the benefit is alcoholism or drug problems. Also included are payments for people claiming the lowest level of one of the two Disability Living Allowance (DLA) components at 20.55 a week. The actual total for Barrow, Copeland and South Lakeland could be up to 10,000 higher depending on what level and components of DLA the 90 claimants across the three areas qualify for. The annual cost for the three areas is 1.66m 739,024 for Barrow, 494,598 for Copeland and 443,040 for South Lakeland. A breakdown shows there are 50 people claiming incapacity benefit paid at 99.15 after 12 months for alcohol dependency in Barrow, 40 in Copeland and 30 in South Lakeland. A further 30 people in Barrow cite drugs as the reason they cannot work, along with 20 in each of Copeland and South Lakeland. For Employment and Support Allowance, … Continue reading

Posted in Drug Dependency | Comments Off on Cost of supporting South Cumbria addicts is revealed

Page 6,611«..1020..6,6106,6116,6126,613..6,6206,630..»